Free Trial

AC Immune's (ACIU) "Sell (D-)" Rating Reiterated at Weiss Ratings

AC Immune logo with Medical background

Key Points

  • AC Immune's stock rating was reiterated as "Sell (D-)" by Weiss Ratings, indicating negative sentiment among investment analysts.
  • Despite the negative rating, BTIG Research recently issued a "buy" rating with a price target of $8.00, while Zacks Research upgraded the stock to a "hold" rating.
  • AC Immune reported a quarterly loss of ($0.25) EPS, missing estimates, and had revenue of $1.65 million, falling short of expectations of $1.98 million.
  • Five stocks to consider instead of AC Immune.

AC Immune (NASDAQ:ACIU - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Other equities research analysts also recently issued reports about the company. BTIG Research restated a "buy" rating and set a $8.00 price objective on shares of AC Immune in a report on Monday, September 8th. Zacks Research raised AC Immune from a "strong sell" rating to a "hold" rating in a research note on Tuesday, September 9th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $10.00.

Get Our Latest Stock Report on ACIU

AC Immune Trading Down 2.1%

Shares of AC Immune stock traded down $0.08 during trading hours on Wednesday, reaching $3.52. The stock had a trading volume of 150,202 shares, compared to its average volume of 166,275. The firm has a 50 day simple moving average of $2.42 and a two-hundred day simple moving average of $2.04. The firm has a market capitalization of $352.94 million, a price-to-earnings ratio of -6.05 and a beta of 1.56. AC Immune has a 1 year low of $1.43 and a 1 year high of $3.99.

AC Immune (NASDAQ:ACIU - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). The firm had revenue of $1.65 million during the quarter, compared to analysts' expectations of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%. Sell-side analysts forecast that AC Immune will post -0.62 EPS for the current year.

Hedge Funds Weigh In On AC Immune

Large investors have recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise acquired a new position in shares of AC Immune in the 1st quarter worth approximately $50,000. Sei Investments Co. bought a new stake in AC Immune during the 2nd quarter worth approximately $51,000. Assenagon Asset Management S.A. bought a new stake in AC Immune during the 3rd quarter worth approximately $549,000. Acadian Asset Management LLC boosted its position in AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company's stock valued at $679,000 after buying an additional 172,796 shares during the last quarter. Finally, BVF Inc. IL boosted its position in AC Immune by 1.5% in the 1st quarter. BVF Inc. IL now owns 19,822,436 shares of the company's stock valued at $37,068,000 after buying an additional 300,000 shares during the last quarter. Institutional investors and hedge funds own 51.36% of the company's stock.

AC Immune Company Profile

(Get Free Report)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AC Immune Right Now?

Before you consider AC Immune, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.

While AC Immune currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.